SCHEMBL24005643

SCHEMBL24005643

Cc1cc2cc[nH]c2nc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 3/20 0.37
CDK8 P49336 2/20 0.37
FGFR1 P11362 2/20 0.36
KDR P35968 2/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
NTRK1 P04629 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
IGF1R P08069 1/20 0.36
MET P08581 1/20 0.36
PIM1 P11309 1/20 0.36
PRKACA P17612 1/20 0.36
FLT1 P17948 1/20 0.36
LTK P29376 1/20 0.36
GRK5 P34947 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11286572 0.79 AXL (0.39) AXLCDK8FGFR1KDRPRKD3
SCHEMBL5925932 0.79 GPR84 (0.48) AXLCDK8BTKGPR84PIK3CA
SCHEMBL1565089 0.76 AXL (0.41) AXLCDK8FGFR1KDRGPR84
SCHEMBL18012904 0.76 GPR84 (0.45) AXLCDK8FGFR1KDRAURKA
SCHEMBL23147918 0.76 AXL (0.37) AXLCDK8GPR84PIK3CAPIK3CD
SCHEMBL24005741 0.76 RIPK1 (0.42) AXLCDK8FGFR1KDRPRKD3
SCHEMBL9887640 0.76 AXL (0.42) AXLCDK8FGFR1KDRPRKD3
SCHEMBL20783135 0.76 CDK8 (0.34) AXLCDK8FGFR1KDRPRKD3
SCHEMBL25613026 0.76 FEN1 (0.42) AXLCDK8FGFR1KDRGPR84
SCHEMBL24005535 0.73 BRD4 (0.43) AXLCDK8FGFR1KDRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4227311-A1 CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) 2023-08-16 EP disclosed
WO-2023078398-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2023-05-11 WO disclosed
WO-2021223736-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2021-11-11 WO disclosed